Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
STRATTERA (atomoxetine hydrochloride) is a selective norepinephrine reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD) in children and adults. It is the first non-stimulant ADHD medication, offering an alternative mechanism to traditional amphetamine-based treatments. Atomoxetine works by increasing norepinephrine levels in the prefrontal cortex, improving attention and impulse control.
Product is entering loss-of-exclusivity phase with modest Part D presence, signaling reduced commercial team investment and transition focus toward market defense and generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
Worked on STRATTERA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on STRATTERA offers limited growth trajectory and career advancement given its LOE status and modest commercial footprint ($2M Part D spending). Professionals joining this team should expect a focus on defensive market positioning, generic transition planning, and operational efficiency rather than brand-building or commercial expansion.